MC2 Therapeutics to Present at Upcoming Conferences

Copenhagen, February 26^th, 2024 – MC2 Therapeutics, a commercial stage biotech company focused on developing novel treatment paradigms within immunology and inflammation, announces today that its leadership will attend and present at the following industry conferences:

• 17^th Annual European Life Sciences CEO Forum, Zürich February 28^th-29^th (presentation at 3:20pm CET, February 28^th - Track C - Room Panorama C)
• TD Cowen Annual Health Care Conference, Boston March 4^th-6^th (hosting 1:1 meetings with investors on March 4^th at the event)
• American Academy of Dermatology Annual Meeting, San Diego March 8^th-12^th
• Kempen Life Science Conference, Amsterdam April 16^th-17^th (presentation on April 16^th)
• Bio€quity Europe, San Sebastian May 12^th-14^th (presentation time and location to be announced)
  
  

Any webcasts will be available on MC2’s website following the presentations. Please contact us if you would like to arrange a meeting.

About MC2 Therapeutics
MC2 Therapeutics is a commercial stage biotech company focused on developing novel treatment paradigms within immunology and inflammation. Its pioneering approach in immunology is anchored in a deep understanding of skin biology, clinical expertise and cross-silo thinking.

Its pipeline includes two first-in-class drug candidates both in Phase 2 clinical development, with novel modes of action and blockbuster potential in multiple indications (“I&I pipeline in a product”):

• MC2-32: an oral HSP90 inhibitor with unique tissue specific targeting and a new MOA that modulates multiple pro-inflammatory pathways and relevant immune responses.
  
  
• MC2-25: an iso-cyanate scavenger addressing carbamylation of proteins and amino acids in the skin by iso-cyanate, a dissociation product of urea.
  
  

For additional information on MC2 Therapeutics, please visit www.mc2therapeutics.com.

Contacts:
Lonni Goltermann, +45 2018 1111, investor@mc2therapeutics.com

Media: ICR Consilium
Amber Fennell, +44 20 3709 5700, MC2@consilium-comms.com

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.